View results from the 24-month RHAPSODY long-term extension

Finally, a breakthrough treatment

for your patients with recurrent pericarditis¹

Arcalyst Bottle

ARCALYST® (rilonacept) is the first and only FDA-approved treatment indicated for the treatment of recurrent pericarditis and the reduction in risk of recurrence in adults and children 12 years and older¹.

ARCALYST, an IL-1 soluble decoy receptor, blocks the underlying mechanism that drives inflammation in recurrent pericarditis.

ARCALYST at a glance

The Risk of Recurrence

Up to

30^%

of individuals with a first episode of acute pericarditis will experience a recurrence totaling ~40,000 patients.^2,3

Learn more about the prevalence of recurrent pericarditis, the underlying cause of recurrent inflammation, and why reducing the risk of recurrence matters for your patients.

Why ARCALYST?

Breakthrough Results

In the pivotal trial,

96^%

reduction in risk of recurrent pericarditis episodes
(hazard ratio: 0.04; p<0.0001).¹

The efficacy and safety of ARCALYST were evaluated in RHAPSODY, a Phase 3, double-blind, placebo-controlled, event-driven, randomized withdrawal study (N=61).

The primary efficacy endpoint was time to first adjudicated pericarditis recurrence in the randomized withdrawal period.

Clinical results

ONCE-WEEKLY TREATMENT

1x

Once-weekly subcutaneous injection.¹

Get familiar with the safety profile, dosing and administration, and treatment duration of ARCALYST.

Safety, administration, and treatment duration

Access and resources

The Kiniksa OneConnect program was created to help make treatment support simple for healthcare providers and patients.

Start your patient on ARCALYST

Request to speak to a
Clinical Sales Specialist

Important Safety Information

Warnings and Precautions

Interleukin-1 (IL-1) blockade may interfere with the immune response to infections. Treatment with another medication that works through inhibition of IL-1 or inhibition of tumor necrosis factor (TNF) is not recommended as this may increase the risk of serious infection. Serious, life-threatening infections have been reported in patients taking ARCALYST. Do not initiate treatment with ARCALYST in patients with an active or chronic infection.
Discontinue ARCALYST if a patient develops a serious infection.
It is possible that taking drugs such as ARCALYST that block IL-1 may increase the risk of tuberculosis (TB) or other atypical or opportunistic infections.
Although the impact of ARCALYST on infections and the development of malignancies is not known, treatment with immunosuppressants, including ARCALYST, may result in an increase in the risk of malignancies.
Hypersensitivity reactions associated with ARCALYST occurred in clinical trials. Discontinue ARCALYST and initiate appropriate therapy if a hypersensitivity reaction occurs.
Increases in non-fasting lipid profile parameters occurred in patients treated with ARCALYST in clinical trials. Patients should be monitored for changes in their lipid profiles.
Since no data are available, avoid administration of live vaccines while patients are receiving ARCALYST. ARCALYST may interfere with the normal immune response to new antigens, so vaccines may not be effective in patients receiving ARCALYST. It is recommended that, prior to initiation of therapy with ARCALYST, patients receive all recommended vaccinations, as appropriate.

Adverse Reactions

In patients with CAPS or RP, the most common adverse reactions (≥10%) include injection-site reactions and upper respiratory tract infections.
In patients with DIRA, the most common adverse reactions (>10%) include upper respiratory tract infections, rash, otitis media, pharyngitis, and rhinorrhea.

Drug Interactions

In patients being treated with CYP450 substrates with narrow therapeutic indices, therapeutic monitoring of the effect or drug concentration should be performed, and the individual dose of the medicinal product may need to be adjusted.

For more information about ARCALYST, see full Prescribing Information.

Indication

ARCALYST® (rilonacept) is an interleukin-1 blocker indicated for:

Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.
Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older.
Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more.

References

1. ARCALYST. Package insert. Kiniksa Pharmaceuticals (UK), Ltd.; 2021. 2. Cremer PC, Kumar A, Kontzias A, et al. Complicated pericarditis: understanding risk factors and pathophysiology to inform imaging and treatment. J Am Coll Cardiol. 2016;68(21):2311-2328. 3. Data on file #1. Kiniksa Pharmaceuticals (UK), Ltd.

Go Back Continue